Skip to main content

Table 2 Patient characteristics a

From: Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?

 

Offered incentive (N = 481)

Not offered incentive (N = 534)

Age (mean, SD)

66.2 (10.2)

66.3 (9.6)

Sex

  

 Male

281 (58.4)

308 (57.7)

 Female

162 (33.7)

182 (34.1)

 Unknown

38 (7.9)

44 (8.2)

SIMD deprivation categoryb

  

 1–3 (least deprived)

138 (28.7)

134 (25.1)

 4–7

242 (50.3)

274 (51.4)

 8–10 (most deprived)

101 (21.0)

125 (23.5)

Geographic areasb

  

 Angus and Dundee

217 (45.1)

215 (40.3)

 Fife

200 (41.6)

234 (43.9)

 Perth

64 (13.3)

84 (15.8)

Target patient group

  

 FAST

158 (32.9)

174 (32.6)

 SCOT

84 (17.5)

97 (18.2)

 PATHWAY 1

46 (9.6)

47 (8.8)

 PATHWAY 2

101 (21.0)

109 (20.4)

 PATHWAY 3

92 (19.1)

107 (20.0)

  1. aFAST, Febuxostat versus Allopurinol Streamlined Trial; PATHWAY, Prevention and Treatment of Hypertension with Algorithm Guided Therapy, British Heart Foundation–funded trials; SCOT, Standard care versus Celecoxib Outcome Trial; SIMD, SD, Standard deviation; Scottish Index of Multiple Deprivation. Data are mean (SD) or number (%). There were no significant differences between groups bIncludes one patient with missing data.
Back to article page

Trials

ISSN: 1745-6215